Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD 45 19 BRA55 glyco protein RO extra-cellular
- Product Overview:
CD45 is a type I transmembrane glycoprotein that is encoded by the PTPRC gene in humans and is abundantly expressed on nucleated hematopoietic cells.{49671} It contains an extracellular region that binds to glycoproteins and exists in various isoforms in a cell type-, differentiation state-, and activation state-dependent manner.{49671,49676} CD45 also contains two highly conserved cytoplasmic protein tyrosine phosphatase domains that regulate intracellular signaling.{49671} CD45 functions as a negative or positive regulator of antigen receptor signaling in T and B cells through dephosphorylation of Src family kinases in a cell type- and differentiation state-dependent manner.{49676} It also dephosphorylates JAK kinases, inhibiting cytokine and chemokine signaling in leukocytes. Mutations in PTPRC are associated with severe combined immunodeficiency (SCID) in mice and humans.{49672,49673,49674} The number of CD45+ cells is increased in postmortem brain from patients with Alzheimer’s disease.{49675} Increased levels of the CD45 isoform CD45RO have been found on CD19+ lamina propria B cells isolated from patients with Crohn’s disease.{49676} Fluorescently labeled versions of CD45 have commonly been used in flow cytometry as a pan leukocyte marker and to identify certain subsets of hematopoietic stem cells (HSCs).{59858} Cayman’s CD45 Monoclonal Antibody (Clone BRA-55) can be used for flow cytometry (FC), immunocytochemistry (ICC), immunohistochemistry (IHC), and Western blot (WB) applications. The antibody recognizes CD45 at approximately 170 to 220 kDa from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.